PascalFr.i
Exploration
Accueil
Racine
Exploration
Accueil
Racine

La maladie de Parkinson au Canada (serveur d'exploration) - Exploration (Accueil)

Index « PascalFr.i » - entrée « Voie orale »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Voie nigrostriatale < Voie orale < Voie parentérale  Facettes :

List of bibliographic references indexed by Voie orale

Number of relevant bibliographic references: 16.
Ident.Authors (with country if any)Title
002052 (2009) P.-J. Blanchet [Canada] ; B. Lalonde [Canada] ; G.-J. Lavigne [Canada]Douleur orofaciale et désordres oromoteurs
002816 (2006) Kaveh M. Koochesfahani [Canada] ; Raúl De La Fuente-Fernández [Canada, Espagne] ; Vesna Sossi [Canada] ; Michael Schulzer [Canada] ; Lakshmi N. Yatham [Canada] ; Thomas J. Ruth [Canada] ; Stephan Blinder [Canada] ; A. Jon Stoessl [Canada]Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: Positron emission tomographic studies
002918 (2006) Reyniel Cruz-Aguado [Canada] ; Daniella Winkler ; Christopher A. ShawLack of behavioral and neuropathological effects of dietary β-methylamino-L-alanine (BMAA) in mice
002F19 (2003) Jackalina Van Kampen [Canada] ; Harold Robertson [Canada] ; Theo Hagg [Canada] ; Robert Drobitch [Canada]Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease
003301 (2001) Richard Camicioli [États-Unis, Canada] ; Eric Lea [États-Unis] ; John G. Nutt [États-Unis] ; Gary Sexton [États-Unis] ; Barry S. Oken [États-Unis]Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: A pilot study
003345 (2001) Oksana Suchowersky [États-Unis, Canada] ; Peter Bailey ; E. Pourcher ; Lynne Bulger ; Giovanni FacciponteComparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD
003351 (2001) Raul De La Fuente-Fernandez [Canada] ; Jian-Qiang Lu [Canada] ; Vesna Sossi [Canada] ; Salma Jivan [Canada] ; Michael Schulzer [Canada] ; James E. Holden [États-Unis] ; Chong S. Lee [Canada] ; Thomas J. Ruth [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada]Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease : PET evidence of increased dopamine turnover
003797 (1999) Juan Fernandez-Ruiz [États-Unis] ; Doris Doudet [Canada] ; Thomas G. Aigner [États-Unis]Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys
003827 (1999) V. D. Doan [Canada] ; R. Grondin [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada]Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys
003C42 (1997) S. Rohatagi [États-Unis] ; J. S. Barrett [États-Unis] ; K. E. Dewitt [États-Unis] ; D. Lessard [Canada] ; R. J. Morales [États-Unis]Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system
003E88 (1996) P. Sandor [Canada] ; A. E. Lang [Canada] ; S. Singal [Canada] ; C. Augus [Canada]Remoxipride in the treatment of levodopa-induced psychosis
004985 (1990) N. R. C. Campbell ; D. Rankine ; A. E. Goodridge ; B. B. Hasinoff ; M. KaraSinemet-ferrous sulphate interaction in patients with Parkinson's disease
004B28 (1989) W. G. Vincken ; C. M. Darauay ; M. G. CosioReversibility of upper airway obstruction after levodopa therapy in Parkinson's disease
004C02 (1988) Thomas L. Perry [Canada] ; Karen Jones [Canada] ; Shirley Hansen [Canada] ; Richard A. Wall [Canada]2-Phenylpyridine and 3-phenylpyridine, constituents of tea, are unlikely to cause idiopathic Parkinson's disease
004D94 (1987) MOHAMMAD SHENASA ; M. Fromer ; G. Faugere ; R. Nadeau ; R. A. Leblanc ; C. Lambert ; MOHAMMAD ALI SADR-AMELIEfficacy and safety of intravenous and oral diltiazem for Wolff-Parkinson-White syndrome
004F09 (1986) P. J. Bedard ; T. Di Paolo ; P. Falardeau ; R. BoucherChronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-Parkinsonian monkeys. Correlation with [3H]spiperone binding

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/PascalFr.i -k "Voie orale" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/PascalFr.i  \
                -Sk "Voie orale" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    PascalFr.i
   |clé=    Voie orale
}}
Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022